Applications Due May 25th for Up to $600,000 in Funding for Translational Research in Alzheimer's Disease

Thursday, March 29, 2018


Harrington Discovery Institute (Cleveland, OH)  and the Alzheimer's Drug Discovery Foundation (ADDF) have announced a request for proposals for the 2018 ADDF-Harrington Scholar Award. Grants will include financial support of up to $600,000 for a period of 2 years, as well as project management and drug development support from the Harrington Discovery Institute’s Innovation Support Center. Grant applications may be submitted by academic investigators holding an MD and/or PhD or the equivalent and working at accredited universities, research institutions, and medical centers in the US. Applications should offer creative science aimed at slowing, treating, or curing Alzheimer’s disease and/or related dementias and must be submitted online at AlzDiscovery.org/RFPs. Letters of intent will be accepted through May 25, 2018 and up to 3 grants will be awarded by December 31, 2018.

"This is a tremendous opportunity for innovative researchers who seek a cure for Alzheimer's and other dementias," said Jonathan Stamler, MD, President, Harrington Discovery Institute and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at University Hospitals and Case Western Reserve University School of Medicine.

The ADDF was founded in 1998 and is the only public charity focused solely on development of drugs for AD. To date, the ADDF has awarded over $100 million to fund more than 500 Alzheimer's drug discovery programs and clinical trials in 18 countries. 

The Harrington Discovery Institute at University Hospitals in Cleveland, OH was created in 2012 with a $50 million founding gift from the Harrington family and includes the Harrington Discovery Institute and BioMotiv, a for-profit, mission-aligned drug development company that accelerates early discovery into pharma pipelines.

"Developing a drug for Alzheimer's takes significant resources—in terms of both expertise and costs. This partnership was created to give researchers access to more of those resources, so they can develop better drugs more rapidly. It has been very successful, and we are excited to continue the partnership," noted Howard Fillit, MD, Founding Executive Director and Chief Science Officer at the ADDF.

Next Story

Comments

You must be logged in to leave a comment.